Benutzer:Ernesto.simon
Evolva Holding SA
Description
[Bearbeiten | Quelltext bearbeiten]Evolva Holding SA is an international synthetic biology group that works on the discovery and development of novel, differentiated pharmaceutical products that target significant unmet medical needs and on industrial products[1] [2] . The company is headquartered in Reinach, near Basel, Switzerland and has operations in Switzerland, Denmark, India and the United States[3].
Technology and product portfolio
[Bearbeiten | Quelltext bearbeiten]The company uses synthetic biology and its proprietary technology, genetic chemistry, to create small molecule drugs and other compounds [4] [5] . Its product portfolio includes EV-077, which is in Phase I clinical trials to treat proteinuric kidney diseases and cardiovascular diseases; EV-075, which is in pre-clinical stage to treat viral infections, influenza, and haemorrhagic fevers (Ebola) and EV-086, that is in late pre-clinical stage for the treatment of invasive and topical fungal infections. The company’s other products are in early pre-clinical development and comprise EV-021 for E. coli infections and Anthrax; EV-009 for Tularemia and other infections; and EV-050, an antifungal against plant pathogens[6]. It also has a collaboration to apply its technology to the production of vanillin.
History
[Bearbeiten | Quelltext bearbeiten]Evolva’s technology originates from the US company Phytera. The technology was incubated in Denmark before the company was established in Switzerland in 2004. The company quickly expanded its activities by opening or acquiring subsidiaries in Denmark and India (2005) and in the United States (2007). In 2009, Evolva became a public company by merging with Arpida Ltd. to create Evolva Holding SA, listed on the Swiss Stock Exchange under the ticker symbol “EVE” [7] [8]. Evolva applies its technologies to the discovery of novel, differentiated pharmaceutical and industrial products and has contracts relating to drug discovery projects funded by the U. S. Defense Threat Reduction Agency (DTRA), the Army Research Office (ARO), the European Union, Functional Genetics Inc. and Hoffmann–La Roche.
References
[Bearbeiten | Quelltext bearbeiten]- ↑ Evolva annual report 2009.
- ↑ Biotechgate: Evolva SA. Swiss Life Sciences Database
- ↑ Evolva webpage: contact details.
- ↑ Evolva Breeds Small Molecule Drugs Au Naturel. Chemistry & Biology 16(6) pp. 577 – 578, abgerufen am 26. Juni 2009.
- ↑ Yeast artificial chromosomes employed for random assembly of biosynthetic pathways and production of diverse compounds in Saccharomyces cerevisiae. Microbial Cell Factories 2009, 8:45, abgerufen am 13. August 2009.
- ↑ Evolva webpage: compounds.
- ↑ SIX Swiss Exchange: Evolva Holding SA.
- ↑ Swiss Biotech Report 2010. Swiss Biotech